Diagnostic performance of Node-RADS on MRI for a standardized assessment of lymph node metastasis in ovarian cancer
- PMID: 40810810
- DOI: 10.1007/s00261-025-05134-0
Diagnostic performance of Node-RADS on MRI for a standardized assessment of lymph node metastasis in ovarian cancer
Abstract
Objective: The Node-RADS score was proposed and provided a standardized, comprehensive assessment of lymph nodes (LNs), accounting for both size and configuration criteria. This study aimed to evaluate the diagnostic performance of the Node-RADS in LN metastasis of ovarian cancer (OC).
Methods: From December 2018 to April 2023, 81 OC patients who underwent MRI and debulking surgery were included. The likelihood of LN metastasis was assessed by the Node-RADS with MRI. The chi-square test and Fisher's exact test were used to assess the differences in size and configuration between LNs with and without metastasis. The diagnostic performance of Node-RADS and its different criteria for LN metastasis was assessed with receiver operating characteristic (ROC) and area under the curve (AUC).
Results: Among all Node-RADS evaluation criteria, textural changes had the best performance with a sensitivity of 84.6%, a specificity of 78.7%, and a Youden's index of 0.63. At the LN level, the incidence of LN metastasis with Node-RADS scores 1, 2, 3, 4, and 5 was 3.2%, 4.5%, 13.0%, 85.7%, and 86.7%, respectively. The best performance in assessing LN status was observed at Node-RADS scores > 3, with sensitivity, specificity, and Youden's index of 73.1%, 97.8%, and 0.71, respectively. In addition, at the patient and LN levels, the AUC for Node-RADS assessment of LNs was 0.869 and 0.895, respectively.
Conclusion: Node-RADS could be an appropriate choice for structured reporting of LN metastasis in OC. The diagnostic performance of LN metastasis in OC at a Node-RADS score > 3 was satisfactory.
Keywords: Lymph node metastasis; MRI; Node-RADS; Ovarian cancer.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
References
-
- Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23:x111–7. https://doi.org/10.1093/annonc/mds300 - DOI - PubMed
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834 - DOI - PubMed
-
- Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK. Ovarian cancer metastasis: looking beyond the surface. Cancer Cell. 2024;42:1631–6. https://doi.org/10.1016/j.ccell.2024.08.016 - DOI - PubMed
-
- Fournier M, Stoeckle E, Guyon F, Brouste V, Thomas L, MacGrogan G, et al. Lymph node involvement in epithelial ovarian cancer: sites and risk factors in a series of 355 patients. Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc. 2009;19:1307–13. https://doi.org/10.1111/IGC.0b013e3181b8a07c - DOI
-
- Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynecol Obstet. 2021;155:61–85. https://doi.org/10.1002/ijgo.13878 - DOI